These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28442372)

  • 21. Fatty acids for controlled release applications: A comparison between prilling and solid lipid extrusion as manufacturing techniques.
    Vervaeck A; Monteyne T; Siepmann F; Boone MN; Van Hoorebeke L; De Beer T; Siepmann J; Remon JP; Vervaet C
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):173-84. PubMed ID: 26428938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physicochemical characterization by AFM, FT-IR and DSC and biological assays of a promising antileishmania delivery system loaded with a natural Brazilian product.
    Marquele-Oliveira F; Torres EC; Barud Hda S; Zoccal KF; Faccioli LH; Hori JI; Berretta AA
    J Pharm Biomed Anal; 2016 May; 123():195-204. PubMed ID: 26897464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipids bearing extruded-spheronized pellets for extended release of poorly soluble antiemetic agent-Meclizine HCl.
    Qazi F; Shoaib MH; Yousuf RI; Nasiri MI; Ahmed K; Ahmad M
    Lipids Health Dis; 2017 Apr; 16(1):75. PubMed ID: 28403892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of change of matrix crystallinity and polymorphism on ovalbumin release from lipid-based implants.
    Duque L; Körber M; Bodmeier R
    Eur J Pharm Sci; 2018 May; 117():128-137. PubMed ID: 29452211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NIR spectroscopy-a non-destructive analytical tool for protein quantification within lipid implants.
    Schönbrodt T; Mohl S; Winter G; Reich G
    J Control Release; 2006 Aug; 114(2):261-7. PubMed ID: 16872710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro investigation of lipid implants as a controlled release system for interleukin-18.
    Koennings S; Garcion E; Faisant N; Menei P; Benoit JP; Goepferich A
    Int J Pharm; 2006 May; 314(2):145-52. PubMed ID: 16513302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Release pathways of interferon α2a molecules from lipid twin screw extrudates revealed by single molecule fluorescence microscopy.
    Sax G; Feil F; Schulze S; Jung C; Bräuchle C; Winter G
    J Control Release; 2012 Sep; 162(2):295-302. PubMed ID: 22820452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on the lipase-induced degradation of lipid-based drug delivery systems. Part II - Investigations on the mechanisms leading to collapse of the lipid structure.
    Schwab M; McGoverin CM; Gordon KC; Winter G; Rades T; Myschik J; Strachan CJ
    Eur J Pharm Biopharm; 2013 Aug; 84(3):456-63. PubMed ID: 23385286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Solid lipid excipients - matrix agents for sustained drug delivery.
    Rosiaux Y; Jannin V; Hughes S; Marchaud D
    J Control Release; 2014 Aug; 188():18-30. PubMed ID: 24929038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immediate release pellets with lipid binders obtained by solvent-free cold extrusion.
    Krause J; Thommes M; Breitkreutz J
    Eur J Pharm Biopharm; 2009 Jan; 71(1):138-44. PubMed ID: 18805483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro release studies of insulin from lipid implants in solution and in a hydrogel matrix mimicking the subcutis.
    Jensen SS; Jensen H; Møller EH; Cornett C; Siepmann F; Siepmann J; Østergaard J
    Eur J Pharm Sci; 2016 Jan; 81():103-12. PubMed ID: 26478185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low temperature extruded implants based on novel hydrophilic multiblock copolymer for long-term protein delivery.
    Stanković M; de Waard H; Steendam R; Hiemstra C; Zuidema J; Frijlink HW; Hinrichs WL
    Eur J Pharm Sci; 2013 Jul; 49(4):578-87. PubMed ID: 23707467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody.
    Bond MD; Panek ME; Zhang Z; Wang D; Mehndiratta P; Zhao H; Gunton K; Ni A; Nedved ML; Burman S; Volkin DB
    J Pharm Sci; 2010 Jun; 99(6):2582-97. PubMed ID: 20039394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
    Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms controlling protein release from lipidic implants: effects of PEG addition.
    Herrmann S; Winter G; Mohl S; Siepmann F; Siepmann J
    J Control Release; 2007 Apr; 118(2):161-8. PubMed ID: 17275943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of different polymers and drug loads for fused deposition modeling of drug loaded implants.
    Kempin W; Franz C; Koster LC; Schneider F; Bogdahn M; Weitschies W; Seidlitz A
    Eur J Pharm Biopharm; 2017 Jun; 115():84-93. PubMed ID: 28232106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure, stability, and mobility of a lyophilized IgG1 monoclonal antibody as determined using second-derivative infrared spectroscopy.
    Murphy BM; Zhang N; Payne RW; Davis JM; Abdul-Fattah AM; Matsuura JE; Herman AC; Manning MC
    J Pharm Sci; 2012 Jan; 101(1):81-91. PubMed ID: 21918984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controlled release implants based on cast lipid blends.
    Kreye F; Siepmann F; Zimmer A; Willart JF; Descamps M; Siepmann J
    Eur J Pharm Sci; 2011 May; 43(1-2):78-83. PubMed ID: 21463679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted pharmacotherapy of retinal diseases with ranibizumab.
    Campochiaro PA
    Drugs Today (Barc); 2007 Aug; 43(8):529-37. PubMed ID: 17925884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.